ProGripTM Self-Gripping Polyester Mesh in Incisional Hernia Prevention (POETRY)

November 19, 2025 updated by: Medtronic - MITG

Poetry Study - ProGrip™ Self-gripping Polyester Mesh Prospective Embedded REgisTRY for Abdominal Wall Sutureline Reinforcement in Subjects Undergoing Midline Laparotomy to Prevent Incisional Hernia

Interventional, prospective, multicenter, post-marketing clinical follow-up study.

After midline laparotomy, the probability to develop an incisional hernia ranges from 10% to 50% depending on the complexity of the surgery and patient state of health.

As the clinical data needed for the study corresponds with those collected by Club Hernie registry, the clinical study will use the established registry database to collect performance and safety data on the prevention of incisional hernias within 24 months post operatively.

Study Overview

Status

Terminated

Conditions

Detailed Description

The primary objective of this investigation is to confirm the efficacy of ProGrip™ Self-gripping Polyester Mesh to reduce the incidence of incisional hernia within 24 months post-operatively in subjects undergoing procedures with midline laparotomies.

Secondary Objective The secondary objective of this investigation is to confirm the safety of ProGrip™ Self-gripping Polyester Mesh through the occurrence of adverse device effects or procedure related adverse events following the use of ProGrip™ Self- gripping Polyester Mesh in subjects undergoing procedures with midline laparotomies.

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Besançon, France
        • CHU Besançon
      • Bordeaux, France, 33076
        • CHU de BORDEAUX
      • Bordeaux, France
        • CHU de Bordeaux - Hôpital Haut-Lévêque
      • Lille, France
        • CHU Lille
      • Lyon, France
        • HCL Louis Pradel
      • Nantes, France, 44000
        • CHU de Nantes
      • Nîmes, France, 30029
        • CHU de Nîmes
      • Pierre-Bénite, France, 69310
        • Centre Hospitalier Lyon Sud
      • Rennes, France, 35033
        • CHU De Rennes - Hôpital Pontchaillou
      • Rouen, France
        • CHU hopitaux de rouen
      • Strasbourg, France, 67000
        • CHU Strasbourg - Nouvel Hôpital Civil

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Subject has provided informed consent.
  2. Subject is ≥ 18 years of age at the time of consent.
  3. Subject will be undergoing an elective midline laparotomy.
  4. Subject may have a combination of low- and high-risk factors but cannot exceed a total of 5 risk factors or have more than 2 high-risk factors. Subject must have at least 2 low-risk factors if subject does not have any high-risk factors. High- and low-risk factors include:

    1. High-Risk Factors (maximum of 2): i.BMI≥ 35; ii.Prior open abdominal surgery; iii.Daily active smoker or Chronic Obstructive Pulmonary disease (COPD) diagnosis; iv. Current or recent (within 1 year) cancer diagnosis or chemotherapy treatment; v.History of or current abdominal aorta aneurism or surgery for abdominal aortaaneurism
    2. Low-Risk Factors (minimum of 2, if no high-risk factors): i.25 ≤ BMI < 35; ii.Age > 45; iii.Uncontrolled diabetes; iv.Malnutrition as defined by 10% weight loss within the last 3 months; v.Current immunosuppressive treatment; vi.Undergoing colorectal surgery

Exclusion Criteria:

  1. Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where subject is in imminent danger of death.
  2. Subject for which the device is used outside the product IFU, including;

    1. Pregnant women: Women who are known or suspected to be pregnant, or who are planning to become pregnant during the study follow-up period
    2. Subject who has an infection within 30 days of enrollment or, at the time of the surgery, has any active, acute or chronic infection(s) that are uncontrolled and/or requiring treatment such as antibiotics
    3. Subject whose surgical site is contaminated or dirty/infected intraoperatively, as assessed by the Investigator (Exclude Altemeier classification III-IV).
  3. Subject who had received a mesh in a previous ventral hernia repair or has a ventral hernia.
  4. Investigator determined that a planned future surgery would interfere with application of mesh reinforcement.
  5. Subject has participated in an investigational drug or device research study within 30 days of enrollment.
  6. Subject has a life expectancy of <2 years.
  7. Subject has an ASA Physical Status Classification System score >3.
  8. Subject has >5 total risk factors or >2 high-risk factors

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Hernia prevention cohort
single arm safety study, no control arm
Abdominal wall sutureline reinforcement with ProgripTM Self-Gripping Polyester Mesh

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incisional Hernia Rate
Time Frame: 24 months
Incisional hernia rate within 24 months of midline laparotomy assessed by CT-scan and physical examination including hernia clinical examination.
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse Event
Time Frame: From the surgery to the 24-month visit
AE incidence reported by number, seriousness, and relationship to the procedure and device from the surgery to the 24-month visit
From the surgery to the 24-month visit
Time to Incisional Hernia Occurrence
Time Frame: From the surgery to the 24-month visit
Time to incisional hernia occurrence from the surgery to the 24-month visit
From the surgery to the 24-month visit
Post-operative Pain at the Site of Surgery
Time Frame: Day 0, Day 1, Day 8, Month 1, Month 12, Month 24
Post-operative pain at the site of the surgery was measured at days 0, 1, 8 and months 1, 12, 24 using a Visual Analog Scale - a psychometric response scale (0-10) (0 no pain, 10 the worst) either during systematic clinical visit or by phone call when a subject is already discharged. (Worst pain experienced over the last 24 hours).
Day 0, Day 1, Day 8, Month 1, Month 12, Month 24
Quality of Life Questionnaire (QOL) for Patient
Time Frame: Month 1, Month 12, Month 24
Assessment with Club Hernie Registry QOL questionnaire of patients treated with ProGrip Self-Gripping Polyester Mesh for suture line mesh reinforcement. . Two sets of self-administered QOL were administered; one for 1 month and one for 12- and 24-month.
Month 1, Month 12, Month 24
Surgeon Satisfaction
Time Frame: Day 0
Surgeon satisfaction on mesh ease of use and manipulability.
Day 0
Patient Satisfaction
Time Frame: Month 12, Month 24
The Club Hernie Patient Satisfaction Survey is used to determine how satisfied a subject is with the mesh placement.
Month 12, Month 24
Surgeon Satisfaction
Time Frame: Day 0
Time to position the mesh
Day 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Martin Bertrand, MD, Centre Hospitalier Universitaire De Nimes

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 18, 2019

Primary Completion (Actual)

September 12, 2022

Study Completion (Actual)

September 12, 2022

Study Registration Dates

First Submitted

March 21, 2019

First Submitted That Met QC Criteria

April 10, 2019

First Posted (Actual)

April 11, 2019

Study Record Updates

Last Update Posted (Estimated)

December 3, 2025

Last Update Submitted That Met QC Criteria

November 19, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe